The global clinical trials imaging market is expected to USD 981.53 million by 2020 from USD 724.87 million in 2015, at a CAGR of 6.25% between 2015 and 2020. By product, the market includes services & software. The services product segment is further classified into operational imaging services, systems & technology, reader services & design consulting. Based on modality, the market is segmented into CT, MRI, ultrasound, PET, X-rays, ECHO ad other modalities. The CT segment will hold the largest share of the clinical trials imaging market in 2015.
The geographic segments included in this report are North America, Europe, Asia, and Rest of the World (RoW). North America is expected to account for the largest share in the global clinical trials imaging market in 2015. Asia is expected to register the fastest growth.
The growth of this market is mainly driven by growth in pharmaceutical & biotechnology industries, increase in R&D funding and increasing number of CROs. The high growth potential in emerging markets, provides new growth opportunities and development of innovative new imaging modalities, contrast agents, molecular probes & radiopharmaceuticals provides new growth trends to players in the clinical trials imaging market. Rising demand of multimodality imaging technology in clinical trials is the major trend of this market.
A combination of bottom-up and top-down approaches was used to calculate the market sizes and growth rates of the global clinical trials imaging market and its subsegments. All percentage shares, splits, and breakdowns were determined using secondary sources and verified through primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. Primary interviews with key opinion leaders were also used to determine the percentage shares of each...